Sun Pharmaceutical Industries Limited SUNPHARMA NIFTY50NSEAIPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Market & Price

Market Cap

₹4.32 L Cr

Current Price

₹1,799.20

High / Low (52W)

₹1,905.80 / ₹1,553.21

Beta

0.10

Valuation

Stock P/E

37.59

Industry PE

37.60

Forward P/E

27.77

PEG Ratio

1.04

Book Value

₹324.46

Price to Book

5.55

P/S

7.38

EV/EBITDA

24.53

Dividend Yield

0.92%

Profitability & Returns

ROCE

17.94%

ROE

14.72%

ROA

8.43%

Profit Margin

19.64%

Op Margin

18.83%

EPS (Latest Qtr)

₹11.30

EPS (TTM)

₹47.86

Balance Sheet & Liquidity

Debt/Equity

0.06

Quick Ratio

2.12

Current Ratio

2.82

Debt

₹4,627.32 Cr

Total Assets

₹1.09 L Cr

Current Assets

₹63,891.19 Cr

Working Capital

₹41,269.15 Cr

Ownership

Promoter Holding

55.61%

Chg in Prom Hold

FII / Inst Holding

31.34%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

₹4.05 L Cr

Total Revenue (TTM)

₹58,462.04 Cr

EBITDA

₹16,491.22 Cr

Free Cash Flow

₹4,931.94 Cr

Operating Cash Flow

₹12,419.18 Cr

Shares Outstanding

₹239.93 Cr

Gross Margin

80.25%

Payout Ratio

34.52%

Growth (CAGR)

Revenue 5Y

10.39%

Profit 5Y

10.65%

Revenue (YoY)

12.80%

Earnings (YoY)

25.60%

PROS

Compounding revenue at 10.4% over 5 years.
Profit CAGR of 10.6% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
2	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
3	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
4	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
5	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
6	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
7	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
8	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%
9	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	965.10	65.34	₹93,927.75 Cr	0.16%	12.70%	14.33%	23.10%	9.34%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	13,264.22 Cr	13,436.94 Cr	12,815.58 Cr	13,786.07 Cr	15,469.07 Cr	14,559.75 Cr
Cost of Revenue	2,694.20 Cr	2,740.54 Cr	2,637.19 Cr	2,814.76 Cr	2,945.10 Cr	2,801.09 Cr
Gross Profit	10,570.02 Cr	10,696.40 Cr	10,178.39 Cr	10,971.31 Cr	12,523.97 Cr	11,758.66 Cr
Operating Expenses	7,385.06 Cr	7,134.59 Cr	7,417.33 Cr	7,599.24 Cr	8,461.73 Cr	9,006.68 Cr
Operating Income	3,184.96 Cr	3,561.81 Cr	2,761.06 Cr	3,372.07 Cr	4,062.24 Cr	2,751.98 Cr
EBITDA	4,292.96 Cr	4,158.47 Cr	3,967.28 Cr	3,948.12 Cr	5,037.85 Cr	4,412.70 Cr
Interest Expense	69.17 Cr	51.51 Cr	49.14 Cr	74.80 Cr	78.36 Cr	85.89 Cr
Pretax Income	3,597.88 Cr	3,476.40 Cr	3,254.35 Cr	3,172.77 Cr	4,227.16 Cr	3,551.34 Cr
Tax Provision	567.21 Cr	558.86 Cr	1,093.71 Cr	870.15 Cr	826.07 Cr	827.67 Cr
Net Income	3,040.16 Cr	2,903.38 Cr	2,149.88 Cr	2,278.63 Cr	3,368.81 Cr	2,714.03 Cr
Diluted EPS	12.70	12.10	9.00	9.50	14.00	11.30

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	43,278.87 Cr	47,758.45 Cr	52,041.25 Cr	58,220.11 Cr
Cost of Revenue	-	11,942.42 Cr	12,069.66 Cr	10,747.36 Cr	11,543.68 Cr
Gross Profit	-	31,336.45 Cr	35,688.79 Cr	41,293.89 Cr	46,676.43 Cr
Operating Expenses	-	22,059.09 Cr	25,220.76 Cr	28,783.12 Cr	33,123.06 Cr
Operating Income	-	9,277.36 Cr	10,468.03 Cr	12,510.77 Cr	13,553.37 Cr
EBITDA	-	12,110.86 Cr	13,883.15 Cr	16,558.88 Cr	18,395.64 Cr
Interest Expense	-	172.00 Cr	238.47 Cr	231.36 Cr	338.91 Cr
Pretax Income	-	9,408.43 Cr	11,087.89 Cr	13,752.13 Cr	15,118.88 Cr
Tax Provision	-	847.59 Cr	1,439.45 Cr	2,772.03 Cr	3,554.36 Cr
Net Income	-	8,473.58 Cr	9,576.38 Cr	10,929.04 Cr	11,479.42 Cr
Diluted EPS	-	35.30	39.90	45.60	47.80

Compounded Sales Growth

5 Years:	10.39%
1 Year:	12.80%

Compounded Profit Growth

5 Years:	10.65%
1 Year:	25.60%

Stock Price Performance

1 Year:	+6.89%
6 Months:	+1.69%
3 Months:	+3.86%
1 Month:	+1.15%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	80,743.59 Cr	85,499.65 Cr	92,100.58 Cr	1.09 L Cr
Current Assets	-	39,883.34 Cr	43,474.98 Cr	52,624.47 Cr	63,891.19 Cr
Cash & Equivalents	-	4,623.73 Cr	9,285.65 Cr	10,268.77 Cr	9,770.51 Cr
Inventory	-	10,513.05 Cr	9,868.29 Cr	10,243.33 Cr	11,492.93 Cr
Receivables	-	11,438.51 Cr	11,249.37 Cr	13,046.11 Cr	15,509.67 Cr
Total Liabilities	-	21,428.12 Cr	18,373.71 Cr	19,614.63 Cr	24,905.48 Cr
Current Liabilities	-	19,907.00 Cr	16,984.40 Cr	18,194.21 Cr	22,622.04 Cr
Long Term Debt	-	0	1.33 Cr	2.52 Cr	31.26 Cr
Total Debt	-	6,885.87 Cr	3,273.67 Cr	2,362.19 Cr	4,627.32 Cr
Total Equity	-	55,995.38 Cr	63,666.75 Cr	72,218.02 Cr	83,570.09 Cr
Shares Outstanding	-	239.93 Cr	239.93 Cr	239.93 Cr	239.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	8,984.54 Cr	4,959.33 Cr	12,134.98 Cr	14,072.09 Cr	12,419.18 Cr
Investing Cash Flow	-5,724.74 Cr	-7,943.68 Cr	-690.20 Cr	-5,306.16 Cr	-11,344.05 Cr
Financing Cash Flow	-5,193.46 Cr	2,376.07 Cr	-6,710.16 Cr	-7,905.82 Cr	-2,512.55 Cr
Capital Expenditure	-1,495.04 Cr	-2,085.58 Cr	-2,201.81 Cr	-2,128.58 Cr	-3,609.37 Cr
Free Cash Flow	7,489.50 Cr	2,873.75 Cr	9,933.17 Cr	11,943.51 Cr	8,809.81 Cr
Net Change in Cash	-1,933.66 Cr	-608.28 Cr	4,734.62 Cr	860.11 Cr	-1,437.42 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	72.4%	74.7%	79.3%	80.2%
Operating Margin %	-	21.4%	21.9%	24.0%	23.3%
Net Margin %	-	19.6%	20.1%	21.0%	19.7%
ROE %	-	15.1%	15.0%	15.1%	13.7%
ROCE %	-	15.2%	15.3%	16.9%	15.7%

Shareholding Pattern

Insiders

55.61%

Institutions

31.34%

Public Float

70.59%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUNPHARMA

No recent headlines available.

SUNPHARMA · Healthcare